eli lilly oral glp 1 Lilly's GLP-1 Pill Shows Strong Phase 3 Results Eli Lilly's New Oral GLP-1

Clinical Trial Insights In SURMOUNT-1 and SURPASS trials, Mounjaro showed: Up to 22.5% body weight reduction in non-diabetic obese patients Greater HbA1c reductions vs Ozempic and insulin in diabetics Reference : Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Reference : mounjaro.lilly.com/hcp/a1c-weight FDA approved Mounjaro for Type 2 Diabetes in 2022, and later for weight loss under the brand Zepbound in Nov 2023 (US)

From T cells, to the brain, #weightloss and much more, there is no simple unifying one size fits all pathway

This mutation results in resistance to activation by protein C (factor V leiden), which, in turn, potentiates the thrombotic risk (D'Angelo and Selhub, 1997

For this purpose, the adjunctive therapeutic use of small molecules that either inhibit or stimulate eryptosis could represent a valid strategy for the treatment or prevention of pathological complications associated with erythrocyte dysfunction